Device Quarterly Reports Might Signal Start of Slow Down
A series of disappointing first quarter numbers could be an early sign of a slow down in medical procedures, which might lead to a tougher environment for medical device companies.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.